Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Low-Dose SQ Rituximab in Untreated CLL/SLL
NCT03788291Phase 2Completed
- Sponsor
- University of Rochester
- Start
- Mar 2019
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by University of Rochester. Primary endpoint: Complete Response Rate at 1 year. Started Mar 2019; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03788291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03788291.